Cardiff Park Advisors LLC purchased a new stake in Cencora, Inc. (NYSE:COR – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,443 shares of the company’s stock, valued at approximately $734,000.
Several other hedge funds also recently modified their holdings of the company. Hantz Financial Services Inc. increased its holdings in Cencora by 13.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,592 shares of the company’s stock worth $480,000 after purchasing an additional 191 shares in the last quarter. Pensioenfonds Rail & OV bought a new position in Cencora in the third quarter valued at about $9,797,000. IFG Advisory LLC boosted its stake in shares of Cencora by 10.0% during the third quarter. IFG Advisory LLC now owns 850 shares of the company’s stock valued at $255,000 after purchasing an additional 77 shares in the last quarter. Phoenix Financial Ltd. boosted its stake in shares of Cencora by 14.6% during the third quarter. Phoenix Financial Ltd. now owns 2,445 shares of the company’s stock valued at $734,000 after purchasing an additional 312 shares in the last quarter. Finally, Aberdeen Group plc boosted its stake in shares of Cencora by 11.7% during the third quarter. Aberdeen Group plc now owns 164,251 shares of the company’s stock valued at $49,316,000 after purchasing an additional 17,218 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.
Insiders Place Their Bets
In other news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.38% of the company’s stock.
Cencora Trading Up 0.0%
NYSE:COR opened at $359.12 on Monday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a debt-to-equity ratio of 3.01, a quick ratio of 0.59 and a current ratio of 0.94. The firm’s fifty day moving average is $327.12 and its 200-day moving average is $317.20. The firm has a market cap of $68.53 billion, a P/E ratio of 20.04, a P/E/G ratio of 1.86 and a beta of 0.58.
Cencora (NYSE:COR – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, topping analysts’ consensus estimates of $4.58 by $0.08. The business had revenue of $88.35 billion during the quarter, compared to the consensus estimate of $87.95 billion. Cencora had a net margin of 1.03% and a return on equity of 110.72%. Cencora’s quarterly revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the firm earned $3.84 earnings per share. Equities analysts expect that Cencora, Inc. will post 19.58 earnings per share for the current year.
Cencora Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be issued a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 13th. This is an increase from Cencora’s previous quarterly dividend of $0.60. Cencora’s dividend payout ratio (DPR) is 14.73%.
Wall Street Analyst Weigh In
COR has been the topic of several research reports. Wells Fargo & Company boosted their price target on Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $330.00 price objective on shares of Cencora in a report on Tuesday, September 8th. Argus lifted their target price on shares of Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Citigroup restated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Twelve equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $368.14.
View Our Latest Stock Report on COR
About Cencora
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
See Also
- Five stocks we like better than Cencora
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
